A subset of immune cells called nonclassical monocytes, previously unknown to reside in the lungs, play a key role in driving primary graft dysfunction (PGD), the leading cause of death after lung transplantation, report researchers. The study demonstrates targeting these cells could lead to novel treatments for PGD, a complication that currently impacts more than half of transplant patients.